Noncoding RNAs in endocrine malignancy

Oncologist

Volumn 19, Issue 5, 2014, Pages 483-491

  Kentwell, Jessica ^a,c   Gundara, Justin S ^a,b,c   Sidhu, Stan B ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Royal North Shore Hospitals   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Endocrine gland neoplasms; Long noncoding RNA; Oncogenes; Small untranslated RNA; Tumor suppressor genes

Indexed keywords

CYCLIN D1; LONG UNTRANSLATED RNA; MICRORNA; PIWI INTERACTING RNA; SOMATOMEDIN B; UNTRANSLATED RNA;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; ENDOCRINE TUMOR; EPIGENETICS; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; METASTASIS; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA SEQUENCE; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ADRENAL TUMOR; GENETICS; PARATHYROID TUMOR; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; HUMANS; MICRORNAS; PARATHYROID NEOPLASMS; PHEOCHROMOCYTOMA; RNA, LONG NONCODING; THYROID NEOPLASMS;

EID: 84900001797     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0458     Document Type: Article

References (110)

1. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011;10:38.
2. Deng G, Sui G. Noncoding RNAinoncogenesis: A new era of identifying key players. IntJ Mol Sci 2013; 14:18319-18349.
3. Mitra SA, Mitra AP, Triche TJ. A central role for long non-coding RNA in cancer. Front Genet 2012; 3:17.
4. Cheetham SW, Gruhl F, Mattick JS et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013;108:2419-2425.
5. Galasso M, Sana ME, Volinia S. Non-coding RNAs:Akeytofuturepersonalizedmoleculartherapy. Genome Med 2010;2:12.
6. Kim T, Reitmair A. Non-coding RNAs: Functional aspects and diagnostic utility in oncology. Int J Mol Sci 2013;14:4934-4968.
7. Shah MY, Calin GA.The mixof two worlds: Non-codingRNAs andhormones. NucleicAcidTher 2013; 23:2-8.
8. Holley CL, Topkara VK. An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther 2011;25:151-159.
9. Mallardo M, Poltronieri P, D'Urso OF. Non-protein coding RNA biomarkers and differential expression in cancers: A review. J Exp Clin Cancer Res 2008;27:19.
10. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-874.
11. Tömböl Z, Szabó PM, Patócs A et al. Differences in microRNA expression profiles of adrenocortical tumors - letter. Clin Cancer Res 2010;16:2915.
12. Hauptman N, Glavač D. Long non-coding RNA in cancer. Int J Mol Sci 2013;14:4655-4669.
13. Shah AA, Leidinger P, Backes C et al. A set of specific miRNAs is connected with murine and human gastric cancer. Genes Chromosomes Cancer 2013;52:237-249.
14. Farazi TA, Spitzer JI, Morozov P et al. miRNAs in human cancer. J Pathol 2011;223:102-115.
15. Redis RS, Berindan-Neagoe I, Pop VI et al. Non-codingRNAsastheranosticsinhumancancers. JCell Biochem 2012;113:1451-1459.
16. Wahid F, Shehzad A, Khan T et al. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010;1803:1231-1243.
17. Duker AL, Ballif BC, Bawle EV et al. Paternally inherited microdeletion at 15q11. 2 confirms a significant rolefor theSNORD116C/DboxsnoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet 2010;18:1196-1201.
18. Liu C, Zhang N. Nanoparticlesin Gene Therapy. Philadelphia, PA: Elsevier Inc., 2011.
19. Iorio MV, Croce CM. Micro RNA involvement in human cancer. Carcinogenesis 2012;33:1126-1133.
20. Liao J, Yu L, Mei Y et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer 2010;9:198.
21. Valleron W, Ysebaert L, Berquet L et al. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lym-phoma. Blood 2012;120:3997-4005.
22. Martens-Uzunova ES, Jalava SE, Dits NF. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012;31:978-991.
23. Dong XY, Rodriguez C, Guo P et al. SnoRNA U50 isacandidatetumor-suppressorgeneat6q14.3witha mutation associated with clinically significant prostate cancer. Hum Mol Genet 2008;17:1031-1042.
24. Dong X-Y, Guo P, Boyd J et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics 2009;36:447-454.
25. Yang Z, Zhu Q, Luo K et al.The7SKsmallnuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001;414:317-322.
26. Frasca F, Rustighi A, Malaguarnera R et al. HMGA1 inhibits the function of p53family members in thyroid cancer cells. Cancer Res 2006;66:2980-2989.
27. Alazami AM, Al-Owain M, Alzahrani F et al. Loss of function mutation in LARP7, chaperone of 7SK ncRNA, causes a syndrome of facial dysmorphism, intellectual disability, and primordial dwarfism. Hum Mutat 2012;33:1429-1434.
28. Maruyama R, Suzuki H, Yamamoto E et al. Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumour Biol 2012;33:277-285.
29. Mattick JS, Taft RJ, Faulkner GJ. Aglobal view of genomic information-moving beyond the gene and the master regulator. Trends Genet 2010;26:21-28.
30. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011;43:904-914.
31. Reis EM, Verjovski-Almeida S. Perspectives of long non-coding RNAs in cancer diagnostics. Front Genet 2012;3:32.
32. Yap KL, Li S, Muñoz-Cabello AM et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcrip-tional silencing of INK4a. Mol Cell 2010;38:662-674.
33. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464: 1071-1076.
34. Valastyan S. Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2012;17:23-32.
35. Silva JM, Boczek NJ, Berres MW et al. LSINCT5is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol 2011;8:496-505.
36. Prensner JR, Iyer MK, Balbin OA et al. Tran-scriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;29:742-749.
37. Chung S, Nakagawa H, Uemura M et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102:245-252.
38. Dekok JB, Verhaegh GW, Roelofs RW et al. DD3 (PCA3),avery sensitive andspecific markertodetect prostate tumors. Cancer Res 2002;62:2695-2698.
39. Tinzl M, Marberger M, Horvath S et al. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004;46: 182-186; discussion 187.
40. Ploussard G, Haese A, Van Poppel H et al. The prostatecancergene3(PCA3)urinetestinmenwith previous negative biopsies: Does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 2010;106:1143-1147.
41. Hube F, Guo J, Chooniedass-Kothari S et al. Alternative splicing of the first intron of the steroid receptor RNA activator (SRA) participates in the generation of coding and noncoding RNA isoforms in breast cancer cell lines. DNA Cell Biol 2006;25:418-428.
42. Verma S, Tabb MM, Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 2009;9:3.
43. Kurisu T, Tanaka T, Ishii J et al. Expression and function of human steroid receptor RNA activator in prostate cancer cells: Role of endogenous hSRA protein in androgen receptor-mediated transcription. Prostate Cancer Prostatic Dis 2006;9:173-178.
44. Chabre O, Libé R, Assie G et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. EndocrRelat Cancer 2013;20:579-594.
45. Iacoangeli A, Lin Y, Morley EJ et al. BC200 RNA in invasive and preinvasive breast cancer. Carcino-genesis 2004;25:2125-2133.
46. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011;21:354-361.
47. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013;1832:1613-1623.
48. Mourtada-Maarabouni M, Pickard MR, Hedge VL et al. GAS5, a non-protein-coding RNA, controls apoptosis and is down regulated in breast cancer. Oncogene 2009;28:195-208.
49. Zaman MS, Maher DM, Khan S et al. Current status and implications of microRNAs in ovarian cancerdiagnosis and therapy. JOvarianRes2012;5:1.
50. Kebebew E, Greenspan FS, Clark OH et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 2005;200:890-896.
51. Roman S, Lin R, Sosa JA. Prognosisofmedullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-2142.
52. Pallante P, Visone R, Croce CM et al. Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocr Relat Cancer 2010;17:F91-F104.
53. Pellegriti G, Frasca F, Regalbuto C et al. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.
54. Fassnacht M, Kreissl MC, Weismann D et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009;123:117-141.
55. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-580.
56. Baloch ZW, Barroeta JE, Walsh J et al. Utility of thyroglobulin measurementinfine-needleaspiration biopsy specimensof lymph nodes in the diagnosis of recurrent thyroid carcinoma. Cytojournal 2008;5:1.
57. Lee JC, Zhao J, Clifton-Bligh RJ et al. Plasma miRNA profile as circulating biomarkers of papillary thyroid carcinoma. J Surg Res 2013;179:248.
58. Nikiforova MN, Tseng GC, Steward D et al. MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-1608.
59. Santarpia L, Calin G, Cote GY et al. Deregulation of miRNA-200 family in medullary thyroid carcinoma modulates the expression of cadherin members and mediates cell adhesion and tight junctions [short call poster 21]. Presented at: 80th Annual Meeting of the American Thyroid Association; September 23-27, 2009; Palm Beach, FL.
60. Abraham D, Jackson N, Gundara JS et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 2011;17:4772-4781.
61. Mian C, Pennelli G, Fassan M et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: Preliminary relationships with RET status and outcome. Thyroid 2012;22:890-896.
62. Gundara JS, Zhao JT, Gill AJ et al. Nodal metastasis microRNA expression correlates with the primary tumour in MTC. ANZ J Surg 2012 [Epub ahead of print].
63. He H, Nagy R, Liyanarachchi S et al. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 2009;69:625-631.
64. Yoon H, He H, Nagy R et al. Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer 2007;121:767-775.
65. Jendrzejewski J, He H, Radomska HS et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic non-coding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA 2012;109:8646-8651.
66. Corbetta S, Vaira V, Guarnieri V. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 2010;17:135-146.
67. Rahbari R, He M, Khanafshar E et al. Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol 2011;18:1158-1165.
68. Vaira V, Elli F, Forno I et al. The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol 2012;49:115-124.
69. Ozata DM, Caramuta S. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011;18:643-655.
70. Singh P, Soon PSH, Feige J-J et al. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol 2012;351:118-128.
71. Soon PSH, Tacon LJ, Gill AJ et al. Mir-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009; 15:7684-7692.
72. Patterson E, Webb R, Weisbrod A et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocy-toma. Endocr Relat Cancer 2012;19:157-166.
73. Tombol Z, Eder K, Kovacs A et al. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol 2010;23:1583-1595.
74. Darr R, Lenders JWM, Hofbauer LC et al. Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab 2012;3:11-26.
75. Sturgeon C, Angelos P. Current approach to pheochromocytoma. Oncology 2006;1:1444.
76. Meyer-Rochow GY, Jackson NE, Conaglen JV et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer 2010; 17:835-846.
77. Chen X, Liang H, Zhang J et al. Horizontal transfer of microRNAs: Molecular mechanisms and clinical applications. Protein Cell 2012;3:28-37.
78. Roldo C, Missiaglia E, Hagan JP et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-4684.
79. Li SC, Essaghir A, Martijn C et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685-696.
80. Kidd M, Lawrence BJ, Alaimo D et al. MiR196a plays a critical role in regulating small intestinal neuroendocrine tumor proliferation and metastasis via HOX/AKT pathway activation. Gastroenterol 2011;140:S-817.
81. Lee HW, Lee EH, Ha SY et al. Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol Int 2012;62:583-591.
82. Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: Cracking the epigenetic code. Endocr Relat Cancer 2013;20:R65-R82.
83. Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.
84. Tetzlaff MT, Liu A, Xu X et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007;18:163-173.
85. Chen YT, Kitabayashi N, Zhou XK et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008;21:1139-1146.
86. Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR-146b-5p regulates signal transduction of TGF-/3 by repressing SMAD4 in thyroid cancer. Oncogene 2012;31:1910-1922.
87. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005;102:19075-19080.
88. Chou CK, Chen RF, Chou FF et al. Mir-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010;20:489-494.
89. Cahill S, Smyth P, Finn SP et al. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 2006;5:70.
90. Weber F, Teresi RE, Broelsch CE et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab2006;91: 3584-3591.
91. Visone R, Pallante P, Vecchione A et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007;26:7590-7595.
92. Mitomo S, Maesawa C, Ogasawara S et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 2008;99:280-286.
93. Takakura S, Mitsutake N, Nakashima M et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008;99:1147-1154.
94. Braun J, Hoang-Vu C, Dralle H et al. Down-regulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010;29:4237-4244.
95. Colamaio M, Cali G, Sarnataro D et al. Let-7a down-regulation playsa role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to targettheFXYD5(Dysadherin) gene. J Clin Endocrinol Metab 2012;97:E2168-E2178.
96. Colamaio M, Borbone E, Russo L et al. Mir-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab 2011;96:E1915-E1924.
97. Yip L, Kelly L, Shuai Y et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011; 18:2035-2041.
98. Hudson J, Duncavage E, Tamburrino A et al. Overexpression of miR-10a and miR-375 and down-regulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol 2013;95:62-67.
99. Jacques C, Guillotin D, Fontaine J-F et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors. J Clin Endocrinol Metab 2013;98:E981-E989.
100. Huang Y, Liao D, Pan L et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Eur J Endocrinol 2013;168:675-681.
101. Wang Z, Zhang H, He L et al. Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther 2013;6:281-287.
102. Chou C-K, Yang KD, Chou F-F et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:E196-E205.
103. Zhang J, Liu Y, Liu Z et al. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci 2013;10:585-592.
104. Wang Z, Zhang H, Zhang P et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol 2013;30:577.
105. Esposito F, Tornincasa M, Pallante P et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab 2012;97:E710-E718.
106. Doghman M, El Wakil A, Cardinaud B et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010;70:4666-4675.
107. Tombol Z, Szabo PM, Molnar V et al. Integrative molecular bioinformatics study of human adrenocortical tumors: MicroRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009;16:895-906.
108. Patterson EE, Holloway AK, Weng J et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011;117: 1630-1639.
109. Ruebel K, Leontovich AA, Stilling GA et al. MicroRNA expression in ileal carcinoid tumors: Downregulation of microRNA-133a with tumor progression. Mod Pathol 2010;23:367-375.
110. Hamfjord J, Stangeland AM, Hughes T et al. Differential expression of miRNAs in colorectal cancer: Comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One 2012;7:e34150.